SCHEMBL7181973

SCHEMBL7181973

COc1cccc(Cl)c1C(=O)Pc1ccc(OCc2ccccc2)cc1C.[LiH]

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
FFAR1 O14842 4/20 0.43
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MAOB P27338 3/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
MDM2 Q00987 1/20 0.42
KMT2A Q03164 1/20 0.42
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185200 0.94 L3MBTL1 (0.48) MRGPRX4L3MBTL1FFAR1MAPTALDH1A1
SCHEMBL7179313 0.94 MRGPRX4 (0.53) MRGPRX4FFAR1ALDH1A1MAOBS1PR1
SCHEMBL7175247 0.91 L3MBTL1 (0.46) MRGPRX4L3MBTL1FFAR1MAPTALDH1A1
SCHEMBL7179941 0.91 MRGPRX4 (0.50) MRGPRX4FFAR1ALDH1A1MAOBS1PR1
Lithium SCHEMBL7175251 0.89 MRGPRX4 (0.44) MRGPRX4L3MBTL1FFAR1MAPTALDH1A1
SCHEMBL7174867 0.87 SMN1; SMN2 (0.46) L3MBTL1MAPTALDH1A1GAASMN1; SMN2
SCHEMBL7179771 0.86 L3MBTL1 (0.45) L3MBTL1FFAR1MAPTMAOBGAA
SCHEMBL7182596 0.86 MAPT (0.43) L3MBTL1MAPTALDH1A1GAASMN1; SMN2
SCHEMBL7190316 0.85 KDM4E (0.41) L3MBTL1FFAR1MAPTALDH1A1GAA
SCHEMBL7180874 0.85 GAA (0.41) L3MBTL1MAPTALDH1A1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MRGPRX4 3913/4885L3MBTL1 302/4885FFAR1 671/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MRGPRX4 4163/4885L3MBTL1 126/4885FFAR1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.